window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : October 2, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

enterprise AI

  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Digital & Data,Medical devices

    OSF HealthCare expands RapidAI clinical AI platform to all 18 hospitals

    OSF HealthCare is expanding its use of RapidAI’s clinical AI [...]

    August 12, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development

    Veeva’s Sebastian Wurst on building the data foundation for enterprise AI

    The promise of AI in commercial biopharma is immense, with [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Digital & Data,Drug Discovery & Development

    Pharma’s AI tipping point: C-suite leaders move from pilots to enterprise scale

    The pharmaceutical sector is accelerating into an enterprise-scale AI future, [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • SKY-0515 shows 1.59-point cUHDRS difference in Huntington’s disease study
    Categories: Central Nervous System, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
  • Oncodesign Services and Nexus BioQuest form preclinical research partnership
    Categories: Advanced Therapies, Biotech & Pharma Business, Research & Development
  • Nabsys EGM detects genomic abnormalities in five-sample leukemia study
    Categories: Genomics and sequencing, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top